TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23739212

Group type: EXPERIMENTAL
Intervention: Dietary intake of sucrose
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Dietary intake of protein
Number of subjects: 143

Group type: COMPARATOR
Intervention: Dietary intake of lactose
Number of subjects: 143
Study: 21704306

Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behaviour therapy for eating disorders (CBT‐E)
Number of subjects: 149
Study: 18359424

Group type: EXPERIMENTAL
Intervention: Gram stain of endotracheal aspirates (EA) and bronchoalveolar lavages (BAL)
Number of subjects: 705
Study: 16476913

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 14551476

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (n = 202)
Number of subjects: 3771

Group type: COMPARATOR
Intervention: No vaccination (n = 101)
Number of subjects: 3771
Study: 10971421

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (9 mmHg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal-pressure pneumoperitoneum (13 mmHg)
Number of subjects: 90
Study: 8792892

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Morphine with droperidol (10mg droperidol/60 mg morphine)
Number of subjects: 40
Study: 1599353

Group type: EXPERIMENTAL
Intervention: 120 mg of sustained-release pseudoephedrine taken twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6229262

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium (0.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of nebulised salbutamol and ipratropium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29905663

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for MST-related PTSD
Number of subjects: 32
Study: 26952223

Group type: EXPERIMENTAL
Intervention: naproxen sodium-codeine phosphate (Group NC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: naproxen sodium (Group N)
Number of subjects: 61
Study: 24716522

Group type: EXPERIMENTAL
Intervention: PNF stretching training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 24096258

Group type: EXPERIMENTAL
Intervention: Red wine (375 ml, 41 g of alcohol)
Number of subjects: 25

Group type: COMPARATOR
Intervention: De-alcoholized red wine (equivalent volume)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Water (equivalent volume)
Number of subjects: 25
Study: 21226862

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rocuronium (0.9 mg/kg)
Number of subjects: 60
Study: 18654010

Group type: EXPERIMENTAL
Intervention: Diabetic patients (DM group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-diabetic patients (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 16571909

Group type: EXPERIMENTAL
Intervention: Trace feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cursor feedback
Number of subjects: 0
Study: 12852989

Group type: EXPERIMENTAL
Intervention: Infusional ambulatory chronotherapy with 5‐FU, folinic acid (FOL) and carboplatin
Number of subjects: 45
Study: 10976785

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists
Number of subjects: 0
Study: 9104623

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sodium chloride placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Stridor score
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dexamethasone pre-treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neurologic impairment
Number of subjects: 26
Study: 7924782

Group type: EXPERIMENTAL
Intervention: Alanine infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SRIH infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hyperglucagonemia study
Number of subjects: 10

Group type: COMPARATOR
Intervention: High GH study
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control study with insulin, glucagon, and GH at replacement doses
Number of subjects: 10
Study: 3172783

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg ethanol
Number of subjects: 12
Study: 29357516

Group type: EXPERIMENTAL
Intervention: -12° head-down tilt (HDT) in ambient air (0.04% CO2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: -12° head-down tilt (HDT) with 0.5% CO2
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (0.04% CO2)
Number of subjects: 6
Study: 28060545

Group type: EXPERIMENTAL
Intervention: AERAS-402 vaccine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25800900

Group type: EXPERIMENTAL
Intervention: TOMUS trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SISTEr trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both studies
Number of subjects: 0
Study: 24889937

Group type: EXPERIMENTAL
Intervention: Combination budesonide/formoterol inhaler as maintenance and reliever therapy ('SMART') regimen
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard regimen (combination budesonide/formoterol inhaler for maintenance and salbutamol as reliever)
Number of subjects: 303
Study: 23110481

Group type: EXPERIMENTAL
Intervention: Ablative fractional carbon dioxide laser treatment at pulse durations of 500, 1,000, 1,500, and 1,800 μs.
Number of subjects: 10
Study: 20488910

Group type: EXPERIMENTAL
Intervention: 850 mg metformin three times a day for 4.3 years
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 18980926

Group type: EXPERIMENTAL
Intervention: Care by a pivot nurse in oncology
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care by clinic nurses
Number of subjects: 170
Study: 15812205

Group type: COMPARATOR
Intervention: No analgesia (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endorectal enema of 1% lidocaine gel (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transrectal periprostatic block (group C)
Number of subjects: 60
Study: 11920457

Group type: COMPARATOR
Intervention: Gemcitabine (GEM) alone (Arm A)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) plus Cisplatin (CDDP) (Arm B)
Number of subjects: 107
Study: 10341691

Group type: EXPERIMENTAL
Intervention: Planimetry measurements
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Point counting measurements
Number of subjects: 11

Group type: COMPARATOR
Intervention: Comparison of planimetry and point counting
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Planimetry
Number of subjects: 11
Study: 9280994

Group type: EXPERIMENTAL
Intervention: Oxygen/nitrous oxide (group I)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Isoflurane in O2 and air (group II)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Propofol in continuous infusion with O2 and air (group III)
Number of subjects: 132

Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum (all groups)
Number of subjects: 132
Study: 1587065

Group type: EXPERIMENTAL
Intervention: 40 mg losartan
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 80 mg losartan
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 120 mg losartan
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3956521

Group type: EXPERIMENTAL
Intervention: pindolol (5 mg t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31366664

Group type: EXPERIMENTAL
Intervention: Personal Energy Planning (PEP) programme, duration 7-9 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study: 30342875

Group type: EXPERIMENTAL
Intervention: Smoking cessation group training programme with financial incentives (vouchers for being abstinent: €50 at the end of training, €50 after 3 months, €50 after 6 months, €200 after 12 months)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Control group received weekly 90‐min session of smoking cessation group training for 7 weeks without financial incentives
Number of subjects: 604
Study: 27328023

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d for 1 year (group A)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d for 30 days followed by 75 mg/d until 1 year (group B)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Policosanol 40 mg/d for 6 months and clopidogrel 75 mg/d for 1 year (group C)
Number of subjects: 350
Study: 25537204

Group type: EXPERIMENTAL
Intervention: Gene therapy for RPE65-LCA
Number of subjects: 15
Study: 22546535

Group type: EXPERIMENTAL
Intervention: Squat exercises on a vibratory platform (platform group, n=11)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Squat exercises without vibration (squat group, n=10)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 32
Study: 19566584

Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 237
Study: 18544723

Group type: EXPERIMENTAL
Intervention: H. perforatum (St John's wort) 300 mg standardized to 0.3% hypericin, taken 3 times daily for 8 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo, matched to H. perforatum, taken 3 times daily for 8 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: H. perforatum (St John's wort)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15809508

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (750-3,000 mg/day)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Calcium carbonate (1,500-9,000 mg/day)
Number of subjects: 800
Study: 11808976

Group type: EXPERIMENTAL
Intervention: Untreated CD patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Treated CD patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 45
Study: 10781212

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 800 mg three times a day
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg three times a day
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 7723797

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) exposure in utero
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) exposure before the 11th week of gestation
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) exposure
Number of subjects: 548
Study: 9114906

Group type: EXPERIMENTAL
Intervention: Budesonide inhaled from a Turbuhaler (1 mg)
Number of subjects: 8
Study: 3987794

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 29994922

Group type: EXPERIMENTAL
Intervention: Xbox-Kinect games (Bowling and 20,000 leaks)
Number of subjects: 11
Study: 27501616

Group type: COMPARATOR
Intervention: 0.5% bupivacaine 30 mL (Gr. B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mixture of 0.5% bupivacaine 20 mL and 2% lidocaine 10 mL (Gr. BL)
Number of subjects: 90
Study: 24671522

Group type: EXPERIMENTAL
Intervention: EC aspirin 100 mg od
Number of subjects: 72

Group type: COMPARATOR
Intervention: EC aspirin 100 mg bid
Number of subjects: 72

Group type: COMPARATOR
Intervention: EC aspirin 200 mg od
Number of subjects: 72

Group type: COMPARATOR
Intervention: Plain aspirin 100 mg od
Number of subjects: 72
Study: 22571201

Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg per day, range 5 to 15)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 460
Study: 20522357

Group type: EXPERIMENTAL
Intervention: 50 microg intrathecal morphine with 8 mg hyperbaric bupivacaine and continuous epidural infusion of 0.2% ropivacaine at 6 mL/hr
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 100 microg intrathecal morphine with 8 mg hyperbaric bupivacaine and continuous epidural infusion of 0.2% ropivacaine at 6 mL/hr
Number of subjects: 76

Group type: COMPARATOR
Intervention: 0 microg intrathecal morphine with 8 mg hyperbaric bupivacaine and continuous epidural infusion of 0.2% ropivacaine at 6 mL/hr
Number of subjects: 76
Study: 17931798

Group type: EXPERIMENTAL
Intervention: Graded Prognostic Assessment (GPA)
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Recursive Partitioning Analysis (RPA)
Number of subjects: 1960

Group type: COMPARATOR
Intervention: Other indices (not specified)
Number of subjects: 1960
Study: 16382040

Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 12480802

Group type: EXPERIMENTAL
Intervention: Isolated isoflavone group (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (n = 20)
Number of subjects: 40
Study: 10360493

Group type: EXPERIMENTAL
Intervention: Shockwave frequency of 1 per second (low frequency)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Shockwave frequency of 4 per second (high frequency)
Number of subjects: 114
Study: 8770849

Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 60 minutes
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 90 minutes
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 60 minutes (primed with recombinant urokinase)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 90 minutes (primed with recombinant urokinase)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: r‐ProUK
Number of subjects: 131
Study: 2202709

Group type: EXPERIMENTAL
Intervention: Combination of dehydroemetine and metronidazole
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Metronidazole 800 mg
Number of subjects: 33
Study: 6999618

Group type: EXPERIMENTAL
Intervention: Thiamphenicol (TAP) 1.5 g daily for 14 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 0.48 g TMP and 2.4 g SMZ daily for 14 days
Number of subjects: 29
Study: 31200107

Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS) over SMA
Number of subjects: 20

Group type: COMPARATOR
Intervention: sham stimulation over SMA
Number of subjects: 20
Study: 28698326

Group type: EXPERIMENTAL
Intervention: MiYoga intervention (mindfulness movement programme based on hatha yoga principles)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MiYoga intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 36
Study: 25769412

Group type: EXPERIMENTAL
Intervention: Nutrigenetic-guided diet (n=30)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard balanced diet (n=21)
Number of subjects: 51
Study: 24041216

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 6
Study: 21394639

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 600 mg PO
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (C) with orange juice
Number of subjects: 38
Study: 20098804

Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarction (MI)
Number of subjects: 49
Study: 17210881

Group type: EXPERIMENTAL
Intervention: Alteplase plus heparin sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 0
Study: 15515199

Group type: EXPERIMENTAL
Intervention: New vaginal cone
Number of subjects: 120

Group type: COMPARATOR
Intervention: FES-Biofeedback
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 11589932

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril 4 mg daily, with optional indapamide)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Combination therapy (perindopril plus indapamide)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Single-drug therapy (perindopril alone)
Number of subjects: 6105
Study: 9751239

Group type: EXPERIMENTAL
Intervention: Niaspan 1.5 g at bedtime
Number of subjects: 223

Group type: COMPARATOR
Intervention: Plain niacin 1.5 g/d after 8 weeks
Number of subjects: 223
Study: 7942122

Group type: EXPERIMENTAL
Intervention: PMA stimulation of human alveolar macrophages, blood monocytes, PMN and lymphocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific stimulus IgE/anti-IgE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemiluminescence assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video-imaging camera
Number of subjects: 0
Study: 2896429

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone therapy (M)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Imaginal desensitization (ID)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both imaginal desensitization and medroxyprogesterone (ID + M)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 30
Study: 30069876

Group type: EXPERIMENTAL
Intervention: Stapler hepatectomy
Number of subjects: 138

Group type: COMPARATOR
Intervention: LigaSure™ transection
Number of subjects: 138
Study: 28028836

Group type: EXPERIMENTAL
Intervention: Specialist-taught PE conducted by specialist PE teachers in 13 schools (two 45-minute sessions/week) from grade 2 to grade 6.
Number of subjects: 359

Group type: COMPARATOR
Intervention: Common-practice PE taught by general classroom teachers in 16 schools (30-60 min/week).
Number of subjects: 359
Study: 25669180

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP)
Number of subjects: 2717

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2717
Study: 23302902

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 20798428

Group type: EXPERIMENTAL
Intervention: myofeedback‐based teletreatment
Number of subjects: 139

Group type: COMPARATOR
Intervention: usual treatment
Number of subjects: 139
Study: 17534379

Group type: EXPERIMENTAL
Intervention: Physostigmine (1.0 mg/h)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mc/kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 16963349

Group type: EXPERIMENTAL
Intervention: Telephone-based counseling
Number of subjects: 9

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9
Study: 12600846

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% of energy, n = 19)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat diet (46% of energy, 41% of energy from fat, n = 18)
Number of subjects: 37
Study: 10962425

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (0.4 microg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (saline solution placebo or no treatment)
Number of subjects: 14
Study: 8993100

Group type: EXPERIMENTAL
Intervention: Chronic Venous Insufficiency Questionnaire (CIVIQ)
Number of subjects: 934
Study: 1289138

Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate instillation before refraction
Number of subjects: 100
Study: 3936031

Group type: EXPERIMENTAL
Intervention: Buserelin treatment
Number of subjects: 29
Study: 31070763

Group type: EXPERIMENTAL
Intervention: modulated electro-hyperthermia (mEHT) treatment at a maximal applied power of 150 W for 1 hour/day
Number of subjects: 19
Study: 29801011

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of gemcitabine (2 g in 100 mL of saline)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Saline (100 mL)
Number of subjects: 406
Study: 27166360

Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg orally 3 times weekly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panobinostat with rituximab
Number of subjects: 40
Study: 24084467

Group type: EXPERIMENTAL
Intervention: Computer-tailored self-help intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic self-help intervention
Number of subjects: 0
Study: 22250656

Group type: EXPERIMENTAL
Intervention: Fish oil (480 mg DHA/720 mg EPA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (coconut oil)
Number of subjects: 41
Study: 20704105

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (22 patients, 92 screws)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional fluoroscopic control (20 patients, 84 screws)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 42
Study: 17433019

Group type: EXPERIMENTAL
Intervention: 8 biopsies per endoscopy with H&E staining
Number of subjects: 125

Group type: COMPARATOR
Intervention: 4 biopsies per endoscopy with H&E staining
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: More than 16 biopsies per endoscopy with H&E staining
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Alcian blue/periodic‐acid Schiff staining
Number of subjects: 125
Study: 15901516

Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Teacher-led intervention
Number of subjects: 1295
Study: 12432968

Group type: COMPARATOR
Intervention: Dapsone 100 mg alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg plus nizatidine 300 mg
Number of subjects: 16
Study: 10597555

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 88
Study: 8619521

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nonexercise (NEX)
Number of subjects: 54
Study: 1849442

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy (high-dose epirubicin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cyclophosphamide, epirubicin, and etoposide)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both treatment modalities
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose epirubicin
Number of subjects: 12